Biocept Awarded US Patent for proprietary Primer-Switch Mutation Detection and Amplification Improvement Platform Used to Detect Rare Cell Mutations, Including Cancer Biomarkers
The issuance of this patent expands
"Our Primer-Switch methodology has the potential to find rare mutations in PCR reactions, especially where the detection of rare genetic events is needed, or in cases where more precise PCR amplification reactions are desired or required," said
About
Forward-Looking Statements Disclaimer Statement
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. To the extent that statements in this release are not strictly historical, including without limitation statements as to our ability to improve the outcomes of patients diagnosed with cancer and the utility and effectiveness of our intellectual property protections, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our
Investor Contact:
LHA Investor Relations
Jcain@lhai.com
310-691-7100
View original content to download multimedia:http://www.prnewswire.com/news-releases/biocept-awarded-us-patent-for-proprietary-primer-switch-mutation-detection-and-amplification-improvement-platform-used-to-detect-rare-cell-mutations-including-cancer-biomarkers-301113782.html
SOURCE